Back to Search Start Over

Predictors and Temporal Trends of Adjuvant Aromatase Inhibitor Use in Breast Cancer

Authors :
Michael A. Bookman
Richard L. Theriault
Rebecca A. Ottesen
Joyce C. Niland
Tiffany H. Svahn
Stephen B. Edge
Anne F. Schott
Melissa E. Hughes
Robert W. Carlson
Jane C. Weeks
Source :
Journal of the National Comprehensive Cancer Network. 7:115-121
Publication Year :
2009
Publisher :
Harborside Press, LLC, 2009.

Abstract

After the first report of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial, adjuvant aromatase inhibitor use increased rapidly among National Comprehensive Cancer Network member institutions. Increased aromatase inhibitor use was associated with older age, vascular disease, overexpression of human epidermal growth factor receptor 2 (HER2), or more advanced stage, and substantial variation was seen among institutions. This article examines adjuvant endocrine therapy in postmenopausal women after the first report of the trial, identifies temporal relationships in aromatase inhibitor use, and examines characteristics associated with choice of endocrine therapy among 4044 postmenopausal patients with hormone receptor-positive nonmetastatic breast cancer presenting from July 1997 to December 2004. Multivariable logistic regression analysis examined temporal associations and characteristics associated with aromatase inhibitor use. Time-trend analysis showed increased aromatase inhibitor and decreased tamoxifen use after release of ATAC results (P < .0001). In multivariable regression analysis, institution (P

Details

ISSN :
15401413 and 15401405
Volume :
7
Database :
OpenAIRE
Journal :
Journal of the National Comprehensive Cancer Network
Accession number :
edsair.doi.dedup.....603ebc5218668b0ab68de74db96c5a00